• Amgen sales slide as copies dig into Sensipar, Neulasta firstwordpharma
    August 01, 2019
    Amgen is contending with some costly losses of exclusivity, and as sales for old stalwarts slide, the drugmaker is shifting its focus to a host of new launches in a bid to grow down the line. 
PharmaSources Customer Service